Semperit (SEM) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Achieved a 21.1% year-on-year increase in EBITDA to EUR 84.9 million, with margin up 2.3 percentage points to 12.5% in 2024, exceeding guidance.
Earnings after tax turned from a EUR 17 million loss in 2023 to a EUR 11.5 million profit in 2024.
Free cash flow nearly doubled to EUR 45.8 million, supporting growth investments and a proposed dividend of EUR 0.50 per share.
Achieved all strategic milestones, including full exit from glove business and acquisition of RICO, sharpening focus on industrial elastomers and engineered technology.
Divisional structure confirmed as growth platform, with cost leadership in Industrial Applications and niche specialization in Engineered Applications.
Financial highlights
Revenue slightly declined by 0.8% to EUR 676.6 million, with volume declines offset by RICO's full-year contribution.
EBITDA increased by over 20% year-over-year, driven by cost savings and operational improvements.
Net debt reduced to EUR 103 million (1.2x EBITDA), with cash reserves at EUR 126 million.
Equity ratio improved to 47.2% at year-end 2024.
Cost reduction program delivered EUR 12.6 million in 2024, totaling EUR 18.4 million since inception.
Outlook and guidance
Operational EBITDA for 2025 expected between EUR 70 million and EUR 90 million, depending on market recovery.
CapEx guidance for 2025 is EUR 60 million (EUR 40 million maintenance, EUR 20 million strategic growth projects).
Targeting operating EBITDA of EUR 120 million in 2026, contingent on market support.
Market recovery anticipated in the second half of 2025, with continued challenging conditions in the first half.
Project expenses for digitalization (oneERP) expected at ~EUR 5 million in 2025.
Latest events from Semperit
- Q3 2025 saw a strong EBITDA rebound and positive earnings, supporting a robust full-year outlook.SEM
Q3 20259 Jul 2026 - Q1 2026 saw strong revenue and EBITDA growth, but geopolitical and raw material risks remain.SEM
Q1 202619 May 2026 - Margin recovery, innovation, and sustainability drive a strong 2026 growth outlook.SEM
Austrian Select Conference23 Apr 2026 - Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025